Can Fite Biopharma Stock Price, News & Analysis (NYSEAMERICAN:CANF)

$1.81 -0.07 (-3.72 %)
(As of 01/17/2018 06:05 AM ET)
Previous Close$1.88
Today's Range$1.76 - $1.90
52-Week Range$1.24 - $2.67
Volume75,300 shs
Average Volume242,580 shs
Market Capitalization$30.30 million
P/E Ratio6.24
Dividend YieldN/A
Beta1.37

About Can Fite Biopharma (NYSEAMERICAN:CANF)

Can Fite Biopharma logoCan Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.

Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:CANF
CUSIPN/A
Phone+972-3-9241114

Debt

Debt-to-Equity RatioN/A
Current Ratio7.29%
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio6.24
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net Margins-2,453.03%
Return on Equity-57.94%
Return on Assets-32.52%

Miscellaneous

Employees7
Outstanding Shares16,000,000

Can Fite Biopharma (NYSEAMERICAN:CANF) Frequently Asked Questions

What is Can Fite Biopharma's stock symbol?

Can Fite Biopharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."

How were Can Fite Biopharma's earnings last quarter?

Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) issued its quarterly earnings data on Monday, November, 27th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.09. Can Fite Biopharma had a negative net margin of 2,453.03% and a negative return on equity of 57.94%. View Can Fite Biopharma's Earnings History.

Where is Can Fite Biopharma's stock going? Where will Can Fite Biopharma's stock price be in 2018?

2 brokers have issued 1-year price targets for Can Fite Biopharma's stock. Their forecasts range from $6.00 to $7.00. On average, they expect Can Fite Biopharma's share price to reach $6.50 in the next year. View Analyst Ratings for Can Fite Biopharma.

Are investors shorting Can Fite Biopharma?

Can Fite Biopharma saw a increase in short interest in December. As of December 29th, there was short interest totalling 45,202 shares, an increase of 54.3% from the December 15th total of 29,295 shares. Based on an average daily volume of 138,119 shares, the days-to-cover ratio is currently 0.3 days.

Who are some of Can Fite Biopharma's key competitors?

Who are Can Fite Biopharma's key executives?

Can Fite Biopharma's management team includes the folowing people:

  • Ilan Cohen, Chairman of the Board (Age 61)
  • Pnina Fishman Ph.D., Chief Executive Officer, Director (Age 67)
  • Motti Farbstein, Chief Financial Officer, Chief Operating Officer (Age 51)
  • Guy Regev, Director (Age 47)
  • Abraham Sartani M.D., Director (Age 68)
  • Israel Shamay, External Director (Age 51)

How do I buy Can Fite Biopharma stock?

Shares of Can Fite Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Can Fite Biopharma's stock price today?

One share of Can Fite Biopharma stock can currently be purchased for approximately $1.81.

How big of a company is Can Fite Biopharma?

Can Fite Biopharma has a market capitalization of $30.30 million. Can Fite Biopharma employs 7 workers across the globe.

How can I contact Can Fite Biopharma?

Can Fite Biopharma's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company can be reached via phone at +972-3-9241114.


MarketBeat Community Rating for Can Fite Biopharma (CANF)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  131
MarketBeat's community ratings are surveys of what our community members think about Can Fite Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Can Fite Biopharma (NYSEAMERICAN:CANF) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.50$6.50$6.50$6.00
Price Target Upside: 316.67% upside392.42% upside288.29% upside145.90% upside

Can Fite Biopharma (NYSEAMERICAN:CANF) Consensus Price Target History

Price Target History for Can Fite Biopharma (NYSEAMERICAN:CANF)

Can Fite Biopharma (NYSEAMERICAN:CANF) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/8/2018Maxim GroupSet Price TargetBuy$7.00View Rating Details
10/31/2017HC WainwrightReiterated RatingBuyView Rating Details
10/18/2016Roth CapitalReiterated RatingBuyView Rating Details
8/29/2016Rodman & RenshawInitiated CoverageBuy$6.00View Rating Details
(Data available from 1/17/2016 forward)

Earnings

Can Fite Biopharma (NYSEAMERICAN:CANF) Earnings History and Estimates Chart

Earnings by Quarter for Can Fite Biopharma (NYSEAMERICAN:CANF)

Can Fite Biopharma (NYSEAMERICAN CANF) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/27/2017Q3 2017($0.13)($0.04)ViewN/AView Earnings Details
9/1/2017Q2 2017($0.13)($0.12)ViewN/AView Earnings Details
5/30/2017Q1 2017($0.09)($0.08)ViewN/AView Earnings Details
3/31/2017Q4 2016($0.08)($0.14)ViewN/AView Earnings Details
11/25/2016Q3 2016($0.12)($0.18)ViewN/AView Earnings Details
8/26/2016Q2 2016($0.14)($0.08)ViewN/AView Earnings Details
5/31/2016Q116($0.09)($0.12)ViewN/AView Earnings Details
4/1/2016Q4 2015($0.07)$0.06ViewN/AView Earnings Details
11/27/2015Q3 2015($0.08)($0.30)ViewN/AView Earnings Details
8/27/2015Q2 2015($0.07)($0.14)ViewN/AView Earnings Details
5/29/2015Q115($0.12)($0.04)ViewN/AView Earnings Details
4/8/2015($0.15)($0.20)ViewN/AView Earnings Details
3/27/2015Q4 2014($0.15)($0.20)ViewN/AView Earnings Details
12/2/2014($0.24)($0.10)ViewN/AView Earnings Details
9/3/2014($0.36)($0.20)ViewN/AView Earnings Details
5/30/2014($0.23)($0.22)ViewN/AView Earnings Details
3/31/2014Q4 2013($0.23)($0.44)ViewN/AView Earnings Details
11/29/2013Q3 2013($0.28)$0.20ViewN/AView Earnings Details
8/29/2013Q2 2013($0.21)($0.26)ViewN/AView Earnings Details
5/30/2013Q1 2013($0.21)($0.41)ViewN/AView Earnings Details
11/11/2012Q3 2012($0.21)$0.25ViewN/AView Earnings Details
8/30/2012Q2 2012($0.21)($0.26)ViewN/AView Earnings Details
5/31/2012Q1 2012($0.21)($0.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Can Fite Biopharma (NYSEAMERICAN:CANF) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Can Fite Biopharma (NYSEAMERICAN:CANF)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Can Fite Biopharma (NYSEAMERICAN CANF)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Can Fite Biopharma (NYSEAMERICAN CANF) News Headlines

Source:
DateHeadline
Can-Fite BioPharma (CANF) Announces Milestones for 2018 - StreetInsider.comCan-Fite BioPharma (CANF) Announces Milestones for 2018 - StreetInsider.com
www.streetinsider.com - January 11 at 9:09 AM
Can Fite Biopharma Ltd (CANF) Short Interest Up 54.3% in DecemberCan Fite Biopharma Ltd (CANF) Short Interest Up 54.3% in December
www.americanbankingnews.com - January 10 at 5:38 PM
Can-Fite (CANF) Enters Distribution Agreement for Piclidenoson in Three European Countries with Gebro HoldingsCan-Fite (CANF) Enters Distribution Agreement for Piclidenoson in Three European Countries with Gebro Holdings
www.streetinsider.com - January 9 at 8:58 AM
Can Fite Biopharma (CANF) Earns "Buy" Rating from Maxim GroupCan Fite Biopharma (CANF) Earns "Buy" Rating from Maxim Group
www.americanbankingnews.com - January 8 at 5:28 PM
Can-Fite Partners with Hadassah Medical Center to Target Unmet Need for NASH Drugs - Baystreet.caCan-Fite Partners with Hadassah Medical Center to Target Unmet Need for NASH Drugs - Baystreet.ca
www.baystreet.ca - January 8 at 5:19 PM
Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings - Business Wire (press release)Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings - Business Wire (press release)
www.businesswire.com - January 8 at 5:19 PM
Can-Fite (CANF) Enters Pact with Hadassah Medical Center to ... - StreetInsider.comCan-Fite (CANF) Enters Pact with Hadassah Medical Center to ... - StreetInsider.com
www.streetinsider.com - January 3 at 5:15 PM
Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASHCan-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH
finance.yahoo.com - January 3 at 8:05 AM
Can-Fite (CANF) Reports on the Progress of Its Phase II Liver ... - StreetInsider.comCan-Fite (CANF) Reports on the Progress of Its Phase II Liver ... - StreetInsider.com
www.streetinsider.com - December 18 at 5:12 PM
Maxim Group Analysts Give Can-Fite BioPharma (CANF) a $7.00 Price TargetMaxim Group Analysts Give Can-Fite BioPharma (CANF) a $7.00 Price Target
www.americanbankingnews.com - December 18 at 3:28 PM
Research Analysts Set Expectations for Can-Fite BioPharma Ltd.s FY2017 Earnings (CANF)Research Analysts Set Expectations for Can-Fite BioPharma Ltd.'s FY2017 Earnings (CANF)
www.americanbankingnews.com - December 4 at 2:22 AM
Can-Fite BioPharma (CANF) Enrolls First Patient in Phase II NAFLD/NASH Study with NamodenosonCan-Fite BioPharma (CANF) Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson
www.streetinsider.com - November 28 at 5:12 PM
Can-Fite BioPharma Ltd. (CANF) Short Interest Down 59.2% in NovemberCan-Fite BioPharma Ltd. (CANF) Short Interest Down 59.2% in November
www.americanbankingnews.com - November 27 at 9:58 PM
Can-Fites Former Subsidiary OphthaliX Successfully Completes ... - Business Wire (press release)Can-Fite's Former Subsidiary OphthaliX Successfully Completes ... - Business Wire (press release)
www.businesswire.com - November 17 at 7:36 PM

SEC Filings

Can Fite Biopharma (NYSEAMERICAN:CANF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Can Fite Biopharma (NYSEAMERICAN:CANF) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Can Fite Biopharma (NYSEAMERICAN CANF) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.